Skye Bioscience to acquire Redx Pharma, rebrand as Fibrx Therapeutics on Nasdaq

Reuters2026/08/14 13:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Skye Bioscience will acquire Redx Pharma, creating a combined Nasdaq-listed fibrosis developer to operate as Fibrx Therapeutics.
Transaction includes about USD 125 million in committed financings, including a USD 68 million PIPE and USD 36 million Series A.
Redmile will provide an equity line facility of up to USD 22 million, tied to the PIPE, with a USD 5 million warrant.
Closing is expected in Q4 2026; Redx management will lead the combined company, headquartered in Alderley Park, UK.
Pro forma ownership: Skye holders 5.38%, Redx holders 46.17%, financing investors 48.45%; Skye holders receive CVRs tied to nimacimab monetization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140933PRIMZONEFULLFEED9810376) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Skye Bioscience to acquire Redx Pharma, rebrand as Fibrx Therapeutics on Nasdaq

You may also like

Crypto prices